A new oral #MSdrug on the scene

After Merck KGaA was forced to pull the Cladribine program it has partnered with Japan's Ono Pharmaceuticals. A new release showed the oral MS drug in the partnership, ONO-4641, eliminated a large percentage of brain lesions which are associated with the disease. The study recruited 407 patients and after 26 weeks of a daily dose, investigators found that the mid-range …